Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Khadeeja, Mohamed"'
Autor:
Iván D Vélez, Tran T Hien, Justin A Green, Ana Martin, Hema Sharma, Victoria M Rousell, John J Breton, Terry B Ernest, Katie Rolfe, Maxine Taylor, Khadeeja Mohamed, Siôn W Jones, Nguyen Hoang Chau, Nhu Thi Hoa, Stephan Duparc, Lionel K Tan, Navin Goyal
Publikováno v:
The Lancet Child & Adolescent Health. 6:86-95
Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7efc705875b4d2ec9fb517e1507d94ec
https://doi.org/10.1016/s2352-4642(21)00328-x
https://doi.org/10.1016/s2352-4642(21)00328-x
Autor:
Mark M Fukuda, Srivicha Krudsood, Khadeeja Mohamed, Justin A Green, Sukhuma Warrasak, Harald Noedl, Ataya Euswas, Mali Ittiverakul, Nillawan Buathong, Sabaithip Sriwichai, R Scott Miller, Colin Ohrt
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187376 (2017)
Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen.This r
Externí odkaz:
https://doaj.org/article/875fefbdd0f1461e8a36b71c7a8cc278
Autor:
Allen Wolstenholme, Sherif El-Harazi, Jyoti Patel, Scott Rasmussen, John T. Thompson, Justin A. Green, Alex Yuan, Azra Hussaini, Jason S. Slakter, David E. Barañano, Alessandro Berni, Gavin C. K. W. Koh, Elizabeth Hardaker, Deborah S. Kelly, Hakop Gevorkyan, John Tonkyn, Hanna Coleman, Keith A. Warren, Siôn W. Jones, Stephan Duparc, Khadeeja Mohamed, Robert C. Sergott, Jessica Ackert
Publikováno v:
Drug Safety
Introduction Tafenoquine has been recently registered for the prevention of relapse in Plasmodium vivax malaria. Objective This study assessed the pharmacodynamic effects of 300-mg single-dose tafenoquine on the retina. Methods This phase I, prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb195b877c87d0493e508869a9ec61c5
https://doi.org/10.1007/s40264-019-00839-w
https://doi.org/10.1007/s40264-019-00839-w
Autor:
Kalehiwot M Wubie, Marcus V. G. Lacerda, Françoise Brand, Kim Fletcher, Alemseged Abdissa, Nillawan Buathong, Elizabeth Hardaker, Harald Noedl, Victoria M Rousell, Ermias Diro, Jörg-Peter Kleim, Monica R. F. Costa, Brian Angus, John J Breton, Alejandro Llanos-Cuentas, Lynda Kellam, Reginaldo Z Mia, Marcelo A M Brito, Martin Casapia, Hans-Peter Beck, Fe Espino, Raul Chuquiyauri, Wuelton Marcelo Monteiro, Rezika Mohammed, Donna D Clover, Fernando Val, Sisay Getie, Justin A. Green, Dhelio Batista Pereira, Daniel Yilma, Stephan Duparc, Mauro Shugiro Tada, Cherinet Abebe, Ahmed Zeynudin, Siôn W. Jones, Khadeeja Mohamed, David L. Saunders, Cletus O Ugwuegbulam, Gavin C. K. W. Koh, Chanthap Lon, Srivicha Krudsood
Publikováno v:
The New England Journal of Medicine
Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d64bc83a97e78715cfe8f83b368a046
https://doi.org/10.1056/nejmoa1710775
https://doi.org/10.1056/nejmoa1710775
Autor:
Iván D. Vélez, Wuelton Marcelo Monteiro, Lindsay Kendall, Siôn W. Jones, Victoria M Rousell, Raul Chuquiyauri, Chayadol S Namaik-Larp, Justin A. Green, Marcus V. G. Lacerda, Graham Craig, Marcelo A M Brito, François Nosten, Gavin C. K. W. Koh, Fernando Val, Cindy S. Chu, Elizabeth Hardaker, Ratchadaporn Papwijitsil, Tran Tinh Hien, Sandra Aruachan, Donna D Clover, Martin Casapia, Alejandro Llanos-Cuentas, Germana Bancone, Brian Angus, Viviana M Wilches, Maria F Villegas, Chau H Nguyen, John J Breton, Stephan Duparc, Monica R. F. Costa, Khadeeja Mohamed
Publikováno v:
The New England Journal of Medicine
BACKGROUND Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed “radical cure.” METHODS We performed a phase 3, prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1301e8e7c12abf617a49c556a3c81afc
https://hdl.handle.net/20.500.12866/6917
https://hdl.handle.net/20.500.12866/6917
Autor:
Siôn W. Jones, Ivan Kostov, Allen Wolstenholm, Stephan Duparc, Khadeeja Mohamed, Gavin C. K. W. Koh, Maxine A. Taylor, Azra Hussaini, Samia Bouhired, Navin Goyal, Justin A. Green
Publikováno v:
Antimicrobial Agents and Chemotherapy
Tafenoquine is in development as a single-dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be coadministered with a blood schizonticide, either chloroquine or artemisinin-based combination therapy (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4799cdbbd7ac3b4f7ce86163f76d3075
http://europepmc.org/articles/PMC5119013
http://europepmc.org/articles/PMC5119013
Autor:
R. Scott Miller, Sabaithip Sriwichai, Harald Noedl, Nillawan Buathong, Mark M. Fukuda, Mali Ittiverakul, Srivicha Krudsood, Colin Ohrt, Sukhuma Warrasak, Khadeeja Mohamed, Justin A. Green, Ataya Euswas
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 11, p e0187376 (2017)
PLoS ONE, Vol 12, Iss 11, p e0187376 (2017)
Background Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed60ae0b65536e898726d7e10f91fea
http://europepmc.org/articles/PMC5679603
http://europepmc.org/articles/PMC5679603
Autor:
Ann K. Miller, Andrew P. Beelen, Sushma Narayan, François Nosten, Germana Bancone, Supornchai Kongpatanakul, Jörg J. Möhrle, Ammar Qureshi, Ronnatrai Rueangweerayut, Nushara Yubon, Justin A. Green, Jörg-Peter Kleim, Emma J. Harrell, Vicki Rousell, Stephan Duparc, Khadeeja Mohamed, Lucio Luzzatto
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abde1bc5cfbf1e968bc43e52268bcf02
https://doi.org/10.4269/ajtmh.16-0779
https://doi.org/10.4269/ajtmh.16-0779
Autor:
Ronnatrai, Rueangweerayut, Germana, Bancone, Emma J, Harrell, Andrew P, Beelen, Supornchai, Kongpatanakul, Jörg J, Möhrle, Vicki, Rousell, Khadeeja, Mohamed, Ammar, Qureshi, Sushma, Narayan, Nushara, Yubon, Ann, Miller, François H, Nosten, Lucio, Luzzatto, Stephan, Duparc, Jörg-Peter, Kleim, Justin A, Green
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::71d3486e0aff71bfb9aa641dc9dd2076
https://pubmed.ncbi.nlm.nih.gov/28749773
https://pubmed.ncbi.nlm.nih.gov/28749773
Publikováno v:
Obstetrical & Gynecological Survey. 70:151-153
OBJECTIVE Pregnant women with undiagnosed diabetes are a high-risk group that may benefit from early intervention. Extrapolating from nonpregnancy data, HbA1c ≥6.5% (48 mmol/mol) is recommended to define diabetes in pregnancy. Our aims were to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87483f06178a9acf38d38006f937565b
https://doi.org/10.1097/01.ogx.0000462910.33698.ae
https://doi.org/10.1097/01.ogx.0000462910.33698.ae